Impact of LT3 + LT4 Therapy on Quality of Life in Hypothyroid Patients
Study Overview
This study looked at how combining levothyroxine (LT4) and triiodothyronine (LT3) affects the quality of life in patients with primary hypothyroidism.
Study Details
A total of 151 Iranian patients diagnosed with primary hypothyroidism participated in this trial from 2020 to 2021. Participants were divided into two groups:
- LT4 Group: 80 patients received LT4 only.
- LT4 + LT3 Group: 71 patients received both LT4 and LT3 for at least six months.
Quality of life was measured using the SF-36V1 questionnaire, while clinical and laboratory tests were also conducted.
Key Findings
- The LT4 + LT3 group showed a significant decrease in TSH levels.
- No major differences were found in blood pressure, cholesterol, or body weight between the groups.
- Patients receiving the combination therapy reported better physical functioning and less bodily pain.
- After six months, the physical health scores improved, but the overall quality of life results were still unclear.
Conclusion
Combining LT4 and LT3 may help patients with primary hypothyroidism, especially those with physical discomfort. However, the overall improvement in quality of life needs further investigation.
Trial Registration
This study is registered with the Iranian Registry of Clinical Trials (IRCT) under the number IRCT20200410047012N1.
Importance of Clinical Trials
Clinical trials are essential for developing safe and effective treatments. Our AI-driven platform, DocSym, consolidates clinical standards and research for easier access by healthcare providers.
Enhancing Patient Care
Our mobile apps support the scheduling and monitoring of treatments, making patient care management more efficient. By utilizing AI, clinics can improve workflows, enhance patient outcomes, and reduce paperwork.
To learn more about our solutions, visit aidevmd.com.
